Exagamglogene Autotemcel is a gene-modified cell therapy commercialized by Vertex Pharmaceuticals, with a leading Pre-Registration program in Sickle Cell Disease. According to Globaldata, it is involved in 7 clinical trials, of which 6 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Exagamglogene Autotemcel’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Exagamglogene Autotemcel is expected to reach an annual total of $581 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Exagamglogene Autotemcel Overview
Vertex Pharmaceuticals Overview
Vertex Pharmaceuticals (Vertex) is a biotechnology company that discovers, develops and commercializes transformative drugs for the treatment of serious and life-threatening diseases. The company’s product portfolio includes Trikafta, Symdeko/Symkevi, Orkambi (ivacaftor/lumacaftor), and Kalydeco (ivacaftor) for the treatment of cystic fibrosis. Through its research and development efforts, the company focuses on cystic fibrosis, sickle cell diseases, beta thalassemia, type-1 diabetes and pain. It uses state-of-the-art technology platforms to discover new disease targets, compounds, delivery mechanisms, and treatment modalities. Vertex has R&D centers and commercial offices in North America, South America, Europe, and Australia. The company offers its products in the US, Europe, Australia, and Canada. Vertex is headquartered in Boston, Massachusetts, the US.
The company reported revenues of (US Dollars) US$8,930.7 million for the fiscal year ended December 2022 (FY2022), an increase of 17.9% over FY2021. In FY2022, the company’s operating margin was 48.2%, compared to an operating margin of 36.7% in FY2021. In FY2022, the company recorded a net margin of 37.2%, compared to a net margin of 30.9% in FY2021. The company reported revenues of US$2,374.8 million for the first quarter ended March 2023, an increase of 3.1% over the previous quarter.
For a complete picture of Exagamglogene Autotemcel’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.